Brief: Celltrion Seeks To Get EMA's Approval For Its Covid-19 Treatment's Formal Use
05/10/2021 24:14
Oct 5 (Reuters) -
* CELLTRION: SEEKS TO GET EMA'S APPROVAL FOR ITS COVID-19
TREATMENT'S FORMAL USE
Source text for Eikon: https://bit.ly/2ZQNQlz
Further company coverage: 068270.KS
((Heekyong.Yang@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion, Q3 Operating. Profit 510 Billion Won, Up 69% Y/Y
Brief: Celltrion, To Buy 100 Billion Won Worth Of Own Shares
Brief: Celltrion Sets Mid-To-Long Term Shareholder Return Target To One-Third Of Net Profit
South Korean chip stocks rally, tracking US AI gains; Temasek report adds support
Brief: Celltrion Q2 Operating Profit Rises 77.3% Y/Y To 430 Billion Won